FierceBiotech3h
Cour links up with Roche's Genentech in autoimmune deal that could exceed $940M
Chicago’s Cour Pharmaceuticals—recently honored as one of Fierce Biotech’s 2024 Fierce 15—is bringing its immunology mission ...
FierceBiotech3h
Takeda pays Keros $200M upfront for rival to BMS' booming blockbuster Reblozyl
The outlay, plus up to $1.1 billion in milestones, has secured Takeda ex-China rights to a molecule that could compete with ...
FierceBiotech5h
Ipsen enlists MAITs to take down solid tumors, betting $610M on Biomunex's novel T-cell engagers
Ipsen has gambled up to $610 million on a new class of bispecific T-cell engagers. The biobuck bet has landed the French ...
FierceBiotech21h
GE HealthCare to take over Japanese radiopharmaceutical venture
Physics, makers of diagnostic radiopharmaceuticals and molecular imaging agents. | GE HealthCare plans to take full control ...
FierceBiotech23h
Merus' head and neck cancer candidate bolsters 'best-in-disease' profile with new data drop: analyst
With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...
FierceBiotech23h
Novocure’s tumor treating electric fields clear phase 3 pancreatic cancer trial
Novocure has cleared a phase 3 clinical study in pancreatic cancer, showing its tumor-treating electric fields could help ...